MeiraGtx announces positive data for their AAV-RPGR program to treat X-Linked retinitis pigmentosa

MeiraGTx is very excited to let you know they released positive data for their AAV-RPGR program to treat X-Linked retinitis pigmentosa!  These data are being presented at the American Society for Retina Specialists meeting. Additionally, we announced that based on these encouraging data we will be progressing this program into a Phase 3 study!  
 Please see the press release here. At 8 am we will be hosting a presentation featuring MeiraGTx President and CEO Alexandria Forbes and Phase 1/2 trial investigator Prof. Michel Michaelides to talk about the data. You can view the live presentation and a replay here:
We are extremely happy to be moving forward with the program with our collaboration partner Janssen.